EZH2 GoF
Showing 1 - 25 of 100
Follicular Lymphoma, Refractory Follicular Lymphoma Trial (Tazverik (Tazemetostat))
Not yet recruiting
- Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazverik (Tazemetostat)
- (no location specified)
Oct 6, 2023
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT) Trial in
Active, not recruiting
- Malignant Rhabdoid Tumors (MRT)
- +10 more
-
San Francisco, California
- +31 more
Jan 17, 2023
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis) Trial in Worldwide (MAS825, Placebo)
Recruiting
- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis)
- MAS825
- Placebo
-
Cincinnati, Ohio
- +18 more
Jan 25, 2023
Non Small Cell Lung Cancer Trial in West Los Angeles (Tazemetostat)
Not yet recruiting
- Non Small Cell Lung Cancer
-
West Los Angeles, CaliforniaVA Greater Los Angeles Healthcare System, West Los Angeles, CA
Jul 21, 2022
Breast Cancer Trial in Houston (Trastuzumab deruxtecan, Valemetostat)
Not yet recruiting
- Breast Cancer
- Trastuzumab deruxtecan
- Valemetostat
-
Houston, TexasM D Anderson Cancer Center
Dec 14, 2022
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Japan (Tazemetostat)
Completed
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
-
Nagoya, Aichi, Japan
- +27 more
Nov 18, 2022
DNA Methylation and Histone Modification in H. Pylori Associated
Recruiting
- Gastric Carcinoma
- Immunohistochemical staining for DNMT1 and EZH2
-
Assiut, EgyptAssiut University
Mar 31, 2023
Advanced Follicular Lymphoma:Translational Study From FIL_FOLL12
Not yet recruiting
- Follicular Lymphoma
- EZH2 mutations/CNAs by droplet digital PCR (ddPCR)
- EZH2-derived gene expression signature by RNA-Seq
-
Alessandria, Italy
- +25 more
Apr 4, 2023
Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)
Not yet recruiting
- Relapsed/Refractory Follicular Lymphoma With EZH2
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Jul 20, 2022
Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or
Recruiting
- Triple-negative Breast Cancer
- Pyrotinib with Capecitabine
- +6 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Dabrafenib Mesylate
- +2 more
-
Atlanta, Georgia
- +6 more
Nov 30, 2022
Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)
Suspended
- Solid Tumor
- ARID1A Gene Mutation
-
Greenville, South CarolinaPrisma Health Cancer Institute
Jan 10, 2023
Mesothelioma, BAP1 Loss of Function Trial in France, United Kingdom, United States (Tazemetostat)
Completed
- Mesothelioma
- BAP1 Loss of Function
-
Los Angeles, California
- +15 more
Mar 16, 2021
Solid Tumor, Lymphoma Trial in Beijing (SHR2554+SHR1701, SHR1701)
Recruiting
- Solid Tumor
- Lymphoma
-
Beijing, ChinaDepartment of Biotherapeutic, Chinese PLA General Hospital
Sep 22, 2020
Acute Myeloid Leukemia Trial (Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.)
Unknown status
- Acute Myeloid Leukemia
- Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
- (no location specified)
Jan 1, 2020
Genetic Pathways Leading to Fatty Liver and Atherogenic
Enrolling by invitation
- Non-alcoholic Fatty Liver
- +2 more
- Lipoprotein kinetics
-
Helsinki, Finland
- +1 more
Apr 11, 2022
T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)
Not yet recruiting
- T-cell Lymphoma
- CLL/SLL
- Tazemetostat
- Acalabrutinib and Tazemetostat
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 11, 2023
Lymphoma, B-Cell Trial in Belgium, France (Valemetostat tosylate)
Recruiting
- Lymphoma, B-Cell
- Valemetostat tosylate
-
Bruges, Belgium
- +21 more
Jan 9, 2023
Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)
Recruiting
- Relapsed/Refractory
- Tafasitamab
- +8 more
-
Santa Fe, CaliforniaCalifornia Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022